Wednesday, 29 April 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 29 April 2026
News

Lilly eyes next goldmine

 Posted 29 April 2026 AM

Is Eli Lilly about to strike gold again?

The Indiana giant became the world’s first trillion-dollar pharma last year on the back of its diabetes and weight loss mega blockbusters, leapfrogging GLP-1 pioneer Novo Nordisk. And it has high hopes of repeating the trick with sleep medicine – which may have uses that go well beyond the treatment of narcolepsy.

To see the whole article, please login

Popular

PBAC greenlights new drugs
Lilly refuses PBS listing price
MD's message to Dept workers
CSL falls to nine-year low
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home